The European Medicines Agency (EMA) has continued to monitor the very rare cases of low platelet counts seen after vaccination with Vaxzevria (formerly known as Covid-19 AstraZeneca).
The ESA has initiated a review of vaccination data and disease epidemiology data (including infection rates, hospitalizations, morbidity and mortality). This is being done at the request of the EU Commissioner for Health and Food Safety, following a meeting with EU health ministers.
The assessment by the Committee for Medicinal Products for Human Use (CHMP) will help the authorities to weigh the risks of Vaxzevria against the benefits of the current vaccination campaigns. The evaluation will also consider the need to update the second dose recommendations for people who have already received the first dose of this vaccine.
The ESA considers that, overall, the benefits of the vaccine continue to outweigh its risks to vaccinated individuals. The current evaluation will support the management of national vaccination campaigns and decisions on the optimal distribution of the vaccine.
As with all vaccines, EZA will continue to monitor the safety and efficacy of Vaxzevria and will continue to provide up-to-date information, the Latvian State Agency of Medicines reports.
www.farmacija-mic.lv
–
